StemCell Institute Inc.
7096.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -24.12 | -10.18 | -2.35 | -1.81 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 63.20 | 77.44 | 113.54 | 76.91 |
| Quality | ||||
| ROIC | 1.09% | 1.28% | 1.36% | 2.08% |
| Gross Margin | 61.51% | 61.66% | 61.62% | 62.52% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 6.25% | 7.49% | 18.78% | 34.38% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -23.74 | -21.61 | -27.20 | -23.92 |
| Interest Coverage | 49.21 | 48.08 | 57.06 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 4.75 | 5.02 | 4.81 | 5.10 |
| Cash Conversion Cycle | 269.07 | 264.55 | 268.34 | 247.65 |